argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

Ms. Malini  Moorthy

General Counsel

Mr. Arjen  Lemmen M.Sc.

Vice President of Corporate Development & Strategy

Mr. Timothy  Van Hauwermeiren EMBA, M.B.A., M.Sc.

Chief Executive Officer & Executive Director

Ms. Beth  DelGiacco

Vice President and Global Head of Corporate Communications & Investor Relations

Mr. Karl  Gubitz

Chief Financial Officer

Ms. Andria  Wilk

Global Head of Quality

Mr. Luc  Truyen

Chief Medical Officer

Ms. Karen  Massey

Chief Operating Officer

Mr. Filip  Borgions

Vice President & Global Head of Technical Operations

Mr. Peter  Ulrichts

Chief Scientific Officer

Biotechnology

argenx SE

argenx SE Management Structure

Management information